New therapy set to dominate the HIV market
Gilead Sciences’ new HIV therapeutic Biktarvy has recently gained approval, and is expected...
Trending:
-
![]()
Experts call for a review of pharma manufacturing processes
-
![]()
Marijuana: possible solution to the opioid crisis
-
![Adocia]()
Adocia to begin trial of blood sugar regulation technology
-
![]()
AnaptysBio’s ANB-020 remains a strong potential contender in the peanut allergy market
-
![]()
Incyte’s clinical trial flop indicates an uncertain future for IDO inhibitors
-
![Imfinzi]()
AstraZeneca announces positive results for cancer drug trials
Most Read
Company A-Z
Latest Content
New therapy set to dominate the HIV market
Gilead Sciences’ new HIV therapeutic Biktarvy has recently gained approval, and is expected to have a major impact on the market.
Experts call for a review of pharma manufacturing processes
Industry experts called for a rethink of pharma industry paradigms around manufacturing orphan and cell products at DCAT Week 2018, which took place in New York City last month.
Marijuana: possible solution to the opioid crisis
In 2016, more than 110 people died every day due to opioid overdose in the US. The opioid crisis has reached epidemic levels, and the problem only seems to be growing. A solution to this epidemic is needed, and recent studies suggest that medicinal marijuana may provide some relief. Figure 1 presents the rate of opioid-related deaths in the US from 2007–2017.
Adocia to begin trial of blood sugar regulation technology
French biotech Adocia has announced the initiation of a Phase I study of BioChaperone Pramlintide Insulin, a treatment that could better regulate glucose levels in type 1 diabetes patients.
AnaptysBio’s ANB-020 remains a strong potential contender in the peanut allergy market
Early top-line results from AnaptysBio’s Phase IIa trial of its IL-33-inhibiting biologic, ANB-020, in adult peanut allergy patients were released on March 26.
Incyte’s clinical trial flop indicates an uncertain future for IDO inhibitors
An update on the KEYNOTE-252/ECHO-301 trial for Incyte/Merck’s Phase III drug combo in metastatic melanoma, epacadostat + Keytruda, rocked the biotech industry late last week. News that the once-hopeful drug combo did not meet one of its co-primary endpoints of progression free survival (PFS) sent stock prices for Incyte plummeting by 20%. Although many investors believe this knee-jerk reaction is unwarranted and temporary, it speaks to the importance of epacadostat, a first-in-class indoleamine 2,3-dioxygenase (IDO-1) inhibitor, in the small pharmaceutical company’s pipeline.
AstraZeneca announces positive results for cancer drug trials
AstraZeneca and MedImmune, its global biologics research and development arm, have presented positive trial data for two of its key oncology drugs.
Boehringer and Lilly to support new chronic kidney disease study
Boehringer Ingelheim and Eli Lilly have partnered with the University of Oxford to assess the effects of Jardiance on disease progression and occurrence of cardiovascular death in chronic kidney disease patients.
AstraZeneca deal shows promise for Molecular Partners’ lung cancer therapy
A new epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treatment may be on the horizon for Molecular Partners.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
